Claim

In the 2026 HERBOT phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen had a 95% disease-control rate.

Type QUANTITATIVE · truth-evaluable: yes · status at snapshot: ACTIVE · created seq 18922

26 words; atomic claims are usually under 25

Referenced 82 times: checked 1, looked up by assistants 0, viewed 59, shared 22. A count of attention, not evidence.

Topics

Health · 1efd24fe Public health · 1efd24fe

Assessment

Supported

Score: 0.8808 under ledger-default@0.3.0 at snapshot 27745

2 of 4 review checks done · 1 counted · 1 by the author only

1 independent evidence lineage · review checks 1 of 4 · stability MEDIUM

Main unresolved issue: 5 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:1d92841a-f7a3-8587-8777-d97b55e55a0b

Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.Every quoted passage was confirmed on the page when Galedra fetched it.

Why?

Strongest counted support: The primary trial report gives the disease-control rate as 95% among 40 participants. weight 2.000000 evidence

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Unresolved.

Show calculation

Your view

Registered views

Nobody has registered a view yet.

Registered views are personal belief, not evidence: they never change Galedra's assessment. Affiliations are self-declared and shown only for groups of 5 or more.

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

“In the 2026 HERBOT phase 1b/2 study, a first-line trastuzumab-nivolumab-gemcitabine-cisplatin regimen for HER2-positive advanced biliary tract cancer...” · 2 claims · 29 September 2026

Evidence for

The primary trial report gives the disease-control rate as 95% among 40 participants.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Primary clinical-trial endpoint report.

Evidence against

None.

Qualifications

The quoted passage directly reports a 95% disease-control rate and identifies 40 participants, but it does not itself state the 2026 date, phase 1b/2 design, untreated status, HER2-positive status, or advanced biliary-tract-cancer population.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

It supports the numerical endpoint and sample size while leaving several claim qualifiers unstated.
The 95% disease-control estimate is from 40 enrolled participants at 12 South Korean sites, screened from 49, with 72.5% gallbladder-cancer representation and no prior treatment for advanced/metastatic disease.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
The reported DCR is 95.0% with a two-sided 95% confidence interval of 83.5–99.4 in the 40-participant analysis.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Because the trial is single-arm and nonrandomized without a control arm, the DCR does not establish superiority over standard chemoimmunotherapy; subgroup findings are limited by sample size.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Suppressed as dependent

None.

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

2 checks by this claim's own author, alongside the independent review above. 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	ef4b452a, 4117c8ea, fce623c6, bc0fe833, c20d37ae

Summary

Supported. The main support is: The primary trial report gives the disease-control rate as 95% among 40 participants. 4c6a35fd

Qualifier: The reported DCR is 95.0% with a two-sided 95% confidence interval of 83.5–99.4 in the 40-participant analysis. 6e1c0335

Qualifier: Because the trial is single-arm and nonrandomized without a control arm, the DCR does not establish superiority over standard chemoimmunotherapy; subgroup findings are limited by sample size. 96094972

Qualifier: The quoted passage directly reports a 95% disease-control rate and identifies 40 participants, but it does not itself state the 2026 date, phase 1b/2 design, untreated status, HER2-positive status, or advanced biliary-tract-cancer population. 82551a92

Qualifier: The 95% disease-control estimate is from 40 enrolled participants at 12 South Korean sites, screened from 49, with 72.5% gallbladder-cancer representation and no prior treatment for advanced/metastatic disease. 1e716976

Review checks: 1 of 4. coverage:1d92841a-f7a3-8587-8777-d97b55e55a0b

Generated by stub-v0.1; every sentence cites graph ids.

Contribution history

seq	event	detail
18922	APPENDED
18923	ACCEPT	AUTOMATIC_AFTER_VALIDATION
18934	LINK_EVIDENCE	by 1efd24fe (accepted)
24738	TASK_RESULT	by 1efd24fe (accepted)
25927	TASK_RESULT	by 1efd24fe (accepted)